Traders recall a specific type of morning. Among them was March 9, 2026. Shares of Hims & Hers Health were already skyrocketing before the opening bell, rising 40%, 50%, and even 54% in premarket trading—the kind of move that causes people to stop scrolling and contact their brokers.
The news that drove it arrived late on Friday night, almost casually: the rivalry between Novo Nordisk and Hims & Hers had been resolved. They had completely changed it from a lawsuit to a partnership, not just put an end to it. Wegovy and Ozempic, the company’s popular obesity medications, will now be sold directly through the Hims platform. A month ago, the company had been attempting to legally dismantle Hims.
| Detail | Information |
|---|---|
| Company (Telehealth) | Hims & Hers Health, Inc. (NYSE: HIMS) |
| Headquarters (Hims) | San Francisco, California, USA |
| Founded (Hims) | 2017 |
| CEO (Hims) | Andrew Dudum |
| Company (Pharma) | Novo Nordisk A/S (NYSE: NVO; CPH: NOVO B) |
| Headquarters (Novo) | Bagsværd, Denmark |
| Drugs Involved | Wegovy (semaglutide, weight-loss) and Ozempic (semaglutide, diabetes) — both by Novo Nordisk |
| Settlement Announced | March 9, 2026 |
| Stock Move (HIMS) | +40% to +54% depending on session (premarket vs. open); stock had fallen ~77% from peak prior to deal |
| Stock Move (NVO) | +2.1% on Copenhagen exchange on settlement day |
| Legal Background | Novo sued Hims over compounded semaglutide products sold during GLP-1 drug shortage (2023–2024) |
| Deal Terms | Hims to stop promoting compounded GLP-1 drugs; Novo Nordisk to sell Wegovy and Ozempic directly on Hims platform |
| Competitor Context | Eli Lilly’s Zepbound (tirzepatide) has been gaining obesity market share during this dispute |
| New Drug Development | FDA approved Wegovy HD (semaglutide 7.2 mg) on March 19, 2026, showing ~20.7% mean weight loss |
| Reference | hims.com |
You must know where Hims was sitting prior to this point in order to comprehend why that percentage—40% in a single session—carries the emotional weight it does. From its peak, the stock had dropped by about 77%. A business that appeared to be one of the most notable health-tech success stories of its time had been steadily declining. The end of the GLP-1 drug shortage, along with Novo’s lawsuit, had been steadily depleting Hims’ rocket fuel.
In this case, the backstory is more complicated than the tidy press release version. Hims offered compounded semaglutide, a specially blended form of the same active ingredient, at cheaper costs and quicker delivery than the branded medications during the severe Wegovy and Ozempic shortage in 2023 and 2024, just like many other telehealth providers. The patients were in a desperate situation.
For months, there was a backorder for the branded goods. A real gap was filled by compounded versions. Hims used that gap to build a massive customer base, and as investors saw subscription numbers rise and persuaded themselves that the growth had a long runway, the stock skyrocketed. Tension between the two companies increased when the company’s initial branded drug distribution partnership with Novo Nordisk broke down.
The shortages then subsided. After the FDA ruled that compounded semaglutide was no longer acceptable due to the normalization of supply, Novo Nordisk filed a lawsuit after witnessing its flagship medications being undercut by compounded versions.
The lawsuit was like a verdict on Hims’ whole business strategy. The lawsuit was interpreted by Wall Street, which was already uneasy, as an existential threat, and the stock’s protracted decline continued. As that time passed, it became clear that Hims had created something both genuinely valuable and genuinely vulnerable: a platform with actual patients and a real reach, based on a potentially shifting regulatory framework.
Fundamentally, the reversal that was announced on March 9 is a business decision made by both parties. Calculus is easy to read for Novo Nordisk. In the obesity medication market, Eli Lilly’s Zepbound has been making significant progress, directly challenging Wegovy for patients, prescriptions, and market share. Lilly has been aggressive, establishing its own telehealth adjacency strategy, cutting its own deals, and developing its own direct-to-consumer channels.
After seeing this, Novo might have decided that using Hims is more beneficial to its goals than destroying Hims. Millions of patients on the platform were already receiving GLP-1 treatments. Distribution is that. That is customer acquisition that Novo does not need to handle on its own. The settlement is where leverage turned into a deal; the lawsuit was leverage.
Hims must completely give up compounded GLP-1 promotion in order to comply with the terms. This concession would have seemed disastrous six months ago, but regulatory pressure was already pressing. Hims receives access to the branded medications that its clientele genuinely desires via an official channel, free from the legal cloud. It’s a real business, but it’s a more limited one than the one investors were pricing at their height.
The practical durability of this arrangement is still unknown. The market for GLP-1 is expanding quickly; ten days after the settlement was announced, the FDA approved a higher-dose version of Wegovy, which demonstrated a mean weight loss of about twenty percent in trial data. Additionally, Novo intends to drastically reduce prices for its U.S. market beginning in 2027, which alters the competitive calculations once more. Eli Lilly has also continued to move. Hims is returning to a different landscape than the one it left behind.
A company that was sued into submission by its future partner and recovered forty percent of its market value in a single morning on news that could have just as easily been filed in court two months earlier is a truly bizarre story. It’s possible that both businesses would have benefited from fighting this out first and setting limits before engaging in a relationship that calls for genuine trust.
Alternatively, the lawsuit might have always been a negotiation ploy disguised in legalese, more theater than substance. In any case, on a Monday morning in March, the trade floor received its response, and the figure was 40% higher.
